CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article


Fig. 6. CIITA expression in IRF-2 antisense stable transformants of WM9. A, IRF-2 in antisense IRF-2-transformed WM9 cells. A1, A2, A3, and A4 represent four subclones of WM9 transformed with the antisense IRF-2 expression vector. C1 and C2 represent two subclones of WM9 transformed with the empty vector alone and are used as controls. A total of 20 µg of nuclear extract from each subclone was assayed for IRF-2 by immunoblotting. Immunoblotting of ß-actin was used as a loading control. The relative IRF-2 level was determined by normalizing IRF-2 to ß-actin, as quantified by densitometry. B, constitutive and IFN-{gamma}-induced CIITA expression in IRF-2 antisense stable transformants of WM9. Subclones from IRF-2 antisense transformation (A1, A2, and A4) as well as vector transformation (C1 and C2), were either untreated or treated with 100 or 400 IU of rIFN-{gamma} for 48 h for a CIITA RPA. The relative CIITA level was determined by normalizing CIITA mRNA to {gamma}-actin mRNA. Signals obtained from a short exposure of {gamma}-actin RPA gel (middle panel) were used for quantification. Similar results were obtained with A3 (see panel A, above), i.e., A3 had a reduced level of CIITA expression compared with control transformants (data not shown).





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation